1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Omeros Crashes To All-Time Low On IgAN Failure

 
• By Elizabeth Cairns

Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.      

Business man in suit looking at a red arrow pointing downwards, crashing through the ground in front of him
• Source: Shutterstock

October is not a lucky month for Omeros Corporation. Two years ago, narsoplimab was kicked back by the US Food and Drug Administration in its lead indication of stem cell transplant-associated thrombotic microangiopathy, knocking 26% off the company’s share price. Then yesterday, the company disclosed the failure of a Phase III trial in the drug’s next most advanced indication, immunoglobulin A nephropathy (IgAN).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.